Stockscreener 앱 받기
16.63
0.48%
-0.08
시간 외 거래:
16.60
-0.03
-0.18%
전일 마감가:
$16.71
열려 있는:
$17.15
하루 거래량:
4.03M
Relative Volume:
1.42
시가총액:
$1.84B
수익:
$70.92M
순이익/손실:
$-342.21M
주가수익비율:
-4.4177
EPS:
-3.7644
순현금흐름:
$-304.30M
1주 성능:
+3.04%
1개월 성능:
+3.29%
6개월 성능:
-47.37%
1년 성능:
+10.87%
1일 변동 폭
$16.45
$17.44
1주일 범위
$15.96
$17.44
52주 변동 폭
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
명칭
Viridian Therapeutics Inc
전화
617.272.4600
주소
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
16.63 | 1.84B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 재확인 | Wedbush | Outperform |
| 2025-12-03 | 개시 | William Blair | Outperform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 개시 | TD Cowen | Buy |
| 2024-09-11 | 재확인 | Needham | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-05-09 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 개시 | BTIG Research | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-05-30 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-17 | 개시 | Wells Fargo | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2022-12-19 | 개시 | Cowen | Outperform |
| 2022-12-19 | 개시 | Needham | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-12-01 | 개시 | H.C. Wainwright | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2021-11-18 | 개시 | SVB Leerink | Outperform |
| 2021-10-12 | 개시 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
(VRDN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viridian Therapeutics Inc (VRDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viridian Therapeutics Inc (VRDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Viridian Therapeutics Inc (VRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Viridian Therapeutics Inc (VRDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Viridian Therapeutics Inc (VRDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Viridian Therapeutics Inc (VRDN) Institutional Confidence - TradingKey
Viridian Therapeutics Inc (VRDN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Viridian Therapeutics Inc (VRDN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Viridian Therapeutics Inc (VRDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $35 - Moomoo
VRDN: Approval expected June 30, with launch-ready teams and strong clinical differentiation - TradingView
VRDN News | VIRIDIAN THERAPEUTICS INC (NASDAQ:VRDN) - ChartMill
Viridian Therapeutics stock tumbles after Amgen Tepezza data By Investing.com - Investing.com UK
Viridian Therapeutics stock tumbles after Amgen Tepezza data - Investing.com
VRDN: Ready for TED drug launch in 2026, aiming for broad access and major market expansion - TradingView
[8-K] Viridian Therapeutics, Inc.\DE Reports Material Event - Stock Titan
Viridian Therapeutics (VRDN) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Viridian ties up WuXi supply deal ahead of TED decision - The Pharma Letter
How Investors May Respond To Viridian Therapeutics (VRDN) Debt Repayment And WuXi Manufacturing Pact - Sahm
Viridian Therapeutics (VRDN) Edges Higher Amid Modest Trading ActivityInsider Buying Alerts - newsline.com
Viridian Therapeutics (NASDAQ: VRDN) retires $55.1M Hercules term loan years early - Stock Titan
Viridian Therapeutics to Present at Goldman Sachs and Jefferies Healthcare Conferences in June - geneonline.com
Viridian Therapeutics to Participate in Upcoming June 2026 Investor Conferences - BioSpace
(VRDN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - The Joplin Globe
Viridian Therapeutics secures WuXi deal for veligrotug manufacturing - The Globe and Mail
PDUFA decision nears as Viridian Therapeutics (VRDN) advances TED pipeline and reports Q1 results - MSN
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Viridian Therapeutics, Inc. has reached an agreement with WuXi Biologics, which will manufacture and supply Viridian's investigational drug Veligrotug. - Bitget
Viridian Therapeutics signs manufacturing deal with WuXi Biologics for thyroid eye disease drug - marketscreener.com
Viridian therapeutics enters commercial manufacturing agreement with Wuxi biologics on May 24, 2026 - marketscreener.com
Viridian (VRDN) secures WuXi Biologics pact for long-term veligrotug manufacturing - Stock Titan
Viridian Therapeutics, Inc. Enters Into Commercial Manufacturing Services Agreement With WuXi Biologics - marketscreener.com
Viridian Therapeutics(VRDN) Stock Options Chain | Quotes & News - Moomoo
Does Viridian’s Upsized Note and Equity Offering Change The Bull Case For Viridian Therapeutics (VRDN)? - Sahm
Viridian Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Thyroid Eye Disease PipelineAnalyst Consensus Shift - newsline.com
Viridian Therapeutics prices upsized $350M concurrent stock and convertible notes offerings - MSN
Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M - Insider Monkey
Viridian Therapeutics releases topline phase 3 TED data elegrobart - Eyes On Eyecare
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - AOL.com
Viridian Therapeutics launches $250M concurrent debt and equity offerings - MSN
HighVista Strategies Sells 238,243 Shares of Viridian Therapeutics in Q1 2026News and Statistics - IndexBox
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - The Motley Fool
Why is Viridian Therapeutics stock sinking Monday? - MSN
VRDN: Wedbush Maintains Rating but Lowers Price Target | VRDN St - GuruFocus
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Liquidity Mapping Around (VRDN) Price Events - Stock Traders Daily
VRDN Maintained by Evercore ISI Group -- Price Target Lowered to $26 - GuruFocus
Viridian Therapeutics Analyst Ratings and Price Targets | NASDAQ:VRDN - Benzinga
Viridian Therapeutics Inc (VRDN) Stock Price, Quote, News & History - Benzinga
Bellevue Group (VRDN) files Schedule 13G for 6.6% ownership - Stock Titan
Viridian Therapeutics Inc (VRDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):